Vaishali Pharma share news, announcements and annual reports
NSE: VAISHALIPharmaceuticals & BiotechnologySmall Cap
Vaishali Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2017 · Issue price ₹40
Last close ₹6.42down ₹0.40 (5.87%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹6.82.
30 Oct: open ₹6.82, high ₹6.90, low ₹6.35
52-week range of traded prices to 30 Oct 2026
₹4.75Low, 30 Mar 2026₹10.48High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹87 Cr2,938th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.25
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 6.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,86,88570.6% delivered
Vaishali Pharma share news and announcements
331 announcements, routine notices left out, newest first. Page 2 of 7.
May 2025
24 May · Board meeting
Apr 2025
26 Apr · Management
26 Apr · Amendment to AOA/MOA
Mar 2025
25 Mar · Meeting
Feb 2025
19 Feb · Business
19 Feb · Board meeting
6 Feb · Business
6 Feb · Results
6 Feb · Results
6 Feb · Board meeting
Jan 2025
31 Jan · Legal
Exchange has sought clarification from Vaishali Pharma Limited with respect to announcement dated 28-Jan-2025, regarding " Vaishali Pharma Limited has informed the Exchange regarding Appointment of Mr BhaveshKumar Upadhyay as Independent Director of the company w.e.f. January 28, 2025.". On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the Company is awaited.28 Jan · Board meeting
24 Jan
24 Jan · Board meeting
3 Jan · Management
Nov 2024
14 Nov · Business
14 Nov · Board meeting
14 Nov · Results
Oct 2024
10 Oct · Board meeting
8 Oct · Board meeting
3 Oct · Board meeting
3 Oct · Corporate action
Sep 2024
27 Sep · Meeting
24 Sep · Board meeting
Aug 2024
28 Aug · Board meeting
22 Aug · Board meeting
17 Aug · Corporate action
14 Aug · Business
14 Aug · Results
14 Aug · Board meeting
6 Aug · Board meeting
Jul 2024